This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Will Declining Medical Membership Affect Humana's Q4 Earnings?
by Zacks Equity Research
HUM heads into Q4 with declining medical membership and rising costs, clouding earnings despite expectations for solid revenue growth.
UNHPositive Net Change HUMPositive Net Change CIPositive Net Change ELVPositive Net Change
earnings insurance medical
Centene Incurs Q4 Loss, Revenues Up YoY due to PDP Business Strength
by Zacks Equity Research
CNC incurs a Q4 adjusted loss per share as medical costs spike, but revenues jump nearly 22% on strong PDP and Marketplace premium growth.
CIPositive Net Change HCANegative Net Change CNCNegative Net Change ELVPositive Net Change
earnings medical
Doximity Stock Falls Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DOCS beats Q3 EPS and revenue estimates, but shares plunge 38.5% after hours as margins contract and FY26 revenue guidance is lowered.
ISRGPositive Net Change CAHNegative Net Change PAHCPositive Net Change DOCSNegative Net Change
earnings medical medical-devices
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement?
by Bryan Hayes
The company's market-leading HIV franchise has fueled top-line growth.
GILDPositive Net Change
biotechnology cancer cell-therapy earnings investing medical oncology-screening stock-performance
Ensign Group Q4 Earnings Beat Estimates on Growing Occupancy
by Zacks Equity Research
ENSG tops Q4 EPS estimates as occupancy rose sharply, lifting earnings nearly 20% year over year despite higher costs and a slight revenue miss.
UNHPositive Net Change HCANegative Net Change ENSGPositive Net Change ELVPositive Net Change
earnings medical
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
by Zacks Equity Research
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
BIIBPositive Net Change RHHBYPositive Net Change SUPNPositive Net Change
biotechs earnings medical pharmaceuticals
MCK Q3 Earnings & Sales Top Estimates, 2026 View Up
by Zacks Equity Research
McKesson beats Q3 EPS and revenue estimates, raises fiscal 2026 guidance, and delivers broad-based growth led by oncology, specialty distribution and technology.
ALGNPositive Net Change MCKNegative Net Change ATRCPositive Net Change PAHCPositive Net Change
earnings medical medical-devices
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
by Zacks Equity Research
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
JNJPositive Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
by Debanjana Dey
HIMS is scaling a platform-led digital healthcare model with Labs, AI and YourBio Health, integrating diagnostics, data and care into one ecosystem.
GDRXPositive Net Change HIMSNegative Net Change DOCSNegative Net Change
medical medical-devices
Molina Healthcare Incurs a Loss in Q4 as Medical Costs Surge
by Zacks Equity Research
Molina Healthcare posts Q4 loss as medical costs surge, even as revenues rise 8% and full-year sales top expectations.
UNHPositive Net Change MOHNegative Net Change CIPositive Net Change ELVPositive Net Change
earnings medical